Other than to posture himself as a righteous man, AND FROM MY PERSPECTIVE this is another attempt by a Mahatir loyalist to draw attention away from the real issue that is hanging over the head of Mahatir; ie that scandalous Royal Commission report that calls for the investigation of the notorious "5".
For God's Sake, don't let "bodek" like this Mathias Chang divert your attention from the real work that lies before you as all Malaysians. Mahatir had done irreparable damage to all Malaysians, and this hatefilled racial divied between Malays Vs Chinese must find amiable resolution; we need to unite as ONE NATION and ONE NATIONALITY and we need to hold accountable the man who had exploited the division between Malays vs Chinese to account.
The most important focus for all Malaysians is to PUT PAKATAN RAKYAT INTO GOVERNMENT because only a party that promotes a Malaysian Malaysia will seek reconciliation of all the races in this nation. Just forget that pasky Mathias Chang who seeks his 15 minutes of fame.
What is it that gets Mr Mathias Chang up so riled up on this issue ?
Monday, May 26, 2008
Saturday, May 24, 2008
AN OPINION POSTED ON BLOG " PEOPLE'S PARLIAMENT
WHAT IS MAHATIR OUGHT TO BE THE QUESTION for this discussion rather than who is Mahatir, because there is no who is Mahatir. He is not really a Malay but an Indian but if you called him an Indian he will throw you in detention under the ISA. Is Mahatir a Malay nationalist ? No he is not a Malaysian nationalist either, because by his definition THERE IS NO MALAYSIAN MALAYSIA NATION since by his definition again THERE IS NO MALAYSIAN MALAYSIA. There is a Malaysia, according to him, whose citizens are ALL MALAYS (so if you are a Chinese, Indian or whatever you are not Malaysian, there is no Malaysian), because there cannot be any MALAYSIAN MALAYSIA since such a nation will make MALAYSIAN Chinese, MALAYSIAN Indinas, or WHATEVER MALAYSIANS, fully citizens of Malaysia; and if that is the logical argument then HOW DO YOU FIT A KETUAAN MALAYU into Malaysia ?
We have to assume that Mahatir is a very intelligent person. You know it is not easy to graduate Doctor of the Medical kind from Uni Singapore if you are not at the top of the scale of intelligence, but he is so bloody intelligent that he has had ALL THE MALAYS EATING OFF HIS HAND. It is something that you gallant Malays will not want to see, but really it does exist in the Malay psyche, you love to adopt ICONS, like this Pakistani genius girl who went to Oxford at a tender age ! You lot just simply went ecstatic, what a genius MALAY, and recently you had listed in Fortune 500 Malaysia’s richest man who is Malay, and you went into hoots ! In the same way Mahatir was adopted by the Malays because he is a doctor in those days there were very few Malay doctors. This was the unfortunate thing and it is quite normal that those who BECOME MALAY OR ANYTHING become more Malay or Chinese or Indians than the real Chinese or Indians or whatever ! The tendency to over compensate for what you are not; the tendency to show that you are the real thing you go to lengths to POSTURE BEING ONE.
Mahatir had done a lot that is Bad and retrogressive in shaping what Malaysia had become and all towards posturing himself as MALAY. He did know know what he did was bad for Malaysia and even today most Malays believe that Mahatir had been a true son of the soil (what a description). Mahatir had done this because HE AHD NO VISION, was a leader who is blind to what is good or what is bad. His single most damaging contribution to the Malay race is his NEP and the myth that it benefited the Malays. It is not now that the Malays will see him as the wrecking ball, but in time his legacy will be remembered by all Malaysians as the single most retrogressive influence for the forward progression of the Malays. Mahatir had divided the people of Malaysia as nobody has. THERE IS NO MALAYSIAN MALAYSIA ! There is therefore no Malaysia.
Let the truth be said that for all the fear that may come again like a May 13th, the seed of this fear is sown by Mahatir to cause fear and panic. He thoroughly believes that if he can get AAB out of the Prime Minister’s job he will escape the fate of the recommendations of the Royal Commission; I do not think so because HIS PRESENT CONTRIBUTION TOWARDS UMNO TODAY WILL PAVE THE WAY FORWARD FOR DATO SERI ANWAR TO GET INTO OFFICE; and from there Dato Seri need not so much as to lift a finger to do anything vengeful to Mahatir; he need just let the royal Commission’s recommendations take its natural course and Mahatir will enjoy free food and accommodation at government expense.
We have to assume that Mahatir is a very intelligent person. You know it is not easy to graduate Doctor of the Medical kind from Uni Singapore if you are not at the top of the scale of intelligence, but he is so bloody intelligent that he has had ALL THE MALAYS EATING OFF HIS HAND. It is something that you gallant Malays will not want to see, but really it does exist in the Malay psyche, you love to adopt ICONS, like this Pakistani genius girl who went to Oxford at a tender age ! You lot just simply went ecstatic, what a genius MALAY, and recently you had listed in Fortune 500 Malaysia’s richest man who is Malay, and you went into hoots ! In the same way Mahatir was adopted by the Malays because he is a doctor in those days there were very few Malay doctors. This was the unfortunate thing and it is quite normal that those who BECOME MALAY OR ANYTHING become more Malay or Chinese or Indians than the real Chinese or Indians or whatever ! The tendency to over compensate for what you are not; the tendency to show that you are the real thing you go to lengths to POSTURE BEING ONE.
Mahatir had done a lot that is Bad and retrogressive in shaping what Malaysia had become and all towards posturing himself as MALAY. He did know know what he did was bad for Malaysia and even today most Malays believe that Mahatir had been a true son of the soil (what a description). Mahatir had done this because HE AHD NO VISION, was a leader who is blind to what is good or what is bad. His single most damaging contribution to the Malay race is his NEP and the myth that it benefited the Malays. It is not now that the Malays will see him as the wrecking ball, but in time his legacy will be remembered by all Malaysians as the single most retrogressive influence for the forward progression of the Malays. Mahatir had divided the people of Malaysia as nobody has. THERE IS NO MALAYSIAN MALAYSIA ! There is therefore no Malaysia.
Let the truth be said that for all the fear that may come again like a May 13th, the seed of this fear is sown by Mahatir to cause fear and panic. He thoroughly believes that if he can get AAB out of the Prime Minister’s job he will escape the fate of the recommendations of the Royal Commission; I do not think so because HIS PRESENT CONTRIBUTION TOWARDS UMNO TODAY WILL PAVE THE WAY FORWARD FOR DATO SERI ANWAR TO GET INTO OFFICE; and from there Dato Seri need not so much as to lift a finger to do anything vengeful to Mahatir; he need just let the royal Commission’s recommendations take its natural course and Mahatir will enjoy free food and accommodation at government expense.
Tuesday, May 20, 2008
BIO-TECH GIANT
(Agencies)
Updated: 2008-01-08 10:04
PARIS - China's biotech sector accounts for just a sliver of its pharmaceutical industry and operates under the cloud of a massive review of licenses issued under a regulator executed last year for accepting bribes.
Even so, experts say, Chinese purveyors of genetically engineered drugs and vaccines -- targeting everything from cancer to Alzheimer's -- are growing at a frenzied pace and are likely to become major actors on the world stage.
"There is no question that the sector is established," said Peter Singer of the McLaughlin-Rotman Centre for Global Health in Toronto who was lead researcher of a study published Monday in Nature Biotechnology.
"What we found really surprising is that in an industry that's only 10 years old, China has innovative products on the market," he said.
For their study, Singer and his colleagues selected 22 small- and medium-sized biotech firms from literally thousands operating in the health sector for close scrutiny. They looked for companies that were innovative, both scientifically and in business.
The portrait that emerged is of a dynamic sector that has been growing 30 percent annually over the past decade, reaching a turnover of three billion dollars in the domestic market in 2005.
Yet its activity is dominated by a few big stars and remains dogged by doubts as to its integrity.
It is also a sector led in large measure by "sea turtles" ("hai gui") -- Chinese-born scientists with a decade or two of US or European lab experience under their belts who have come home to found Chinese companies, often with generous backing from the government.
In a market of one billion potential patients, 15 biotech products for health are already on the market, with another 60 in the pipeline, Singer said.
Exhibit A: Gendicine, the first gene therapy product approved after clinical trials anywhere in the world.
A recombinant human adenovirus, Gendicine carries the p53 gene and is administered by injection directly into cancerous tumours in the head and neck, including nasopharyngeal carcinoma.
More than 5,000 patients have received the treatment in combination with radiotherapy, including 400 foreign patients from outside China.
The company became profitable shortly after the launch of the product, approved in 2005 by China's State Drug and Food Administration (SDFA).
That, as it turns out, was not an unimpeachable recommendation.
The SDFA's former director, Zheng Xiaoyu, was executed in July 2007 for accepting bribes in return for issuing drug approvals without proper review.
As a result, a staggering 170,000 licenses granted by the SDFA, especially between 1999 and 2002, are currently under review.
Another company, Shenzhen Beike Technologies, provides a treatment based on umbilical cord and bone marrow stem cells for Alzheimer's, autism, brain trauma, cerebral palsy and spinal cord injury, as well as a dozen other diseases and conditions. The medication is injected directly into the spinal cord of patients.
"There is no need to do clinical trials for this kind of procedure in China," said the study's lead author, Sarah Frew, also a researcher at McLaughlin-Rotman.
"The approach this company is taking is trying the thing on patients rather than doing scientific research," added Singer.
The product has nonetheless been a commercial success, first with Chinese patients and more recently with international patients. When Frew visited the clinic a year ago, there were a dozen foreigners present.
The company's website is filled with glowing testimonials on the effectiveness of the treatment, which costs tens of thousands of dollars.
In most cases the therapies and vaccines developed in China are far less controversial. Indeed, more than 90 percent of products produced in the health biotech sector are biogenerics, with novel products accounting for 3-to-5 percent of the total.
A more recent development are international joint ventures and investment. Shenzhen Chipscreen Biosciences, for example, has developed an anti-cancer drug in cooperation with Huya Bioscience, based in San Diego, California. Once the medication is on the market, the Chinese partner will hold the rights for China, while Huya can lay claim to the rest of the world.
WuXi PharmaTech, which was listed on the New York Stock Exchange in the summer of 2007, is the first biotech service company in China with major foreign clients, including US pharmaceutical giant Merck and Britain's AstraZeneca.
The fact that WuXi has attracted such companies "punctures a little bit the legend that there is no intellectual property in China," said Singer.
Another myth that may soon fall by the wayside is that China can only reproduce what other have done already.
"There is no longer a hegemony on the part of industrialised countries in global biotech innovation," Singer said.
Updated: 2008-01-08 10:04
PARIS - China's biotech sector accounts for just a sliver of its pharmaceutical industry and operates under the cloud of a massive review of licenses issued under a regulator executed last year for accepting bribes.
Even so, experts say, Chinese purveyors of genetically engineered drugs and vaccines -- targeting everything from cancer to Alzheimer's -- are growing at a frenzied pace and are likely to become major actors on the world stage.
"There is no question that the sector is established," said Peter Singer of the McLaughlin-Rotman Centre for Global Health in Toronto who was lead researcher of a study published Monday in Nature Biotechnology.
"What we found really surprising is that in an industry that's only 10 years old, China has innovative products on the market," he said.
For their study, Singer and his colleagues selected 22 small- and medium-sized biotech firms from literally thousands operating in the health sector for close scrutiny. They looked for companies that were innovative, both scientifically and in business.
The portrait that emerged is of a dynamic sector that has been growing 30 percent annually over the past decade, reaching a turnover of three billion dollars in the domestic market in 2005.
Yet its activity is dominated by a few big stars and remains dogged by doubts as to its integrity.
It is also a sector led in large measure by "sea turtles" ("hai gui") -- Chinese-born scientists with a decade or two of US or European lab experience under their belts who have come home to found Chinese companies, often with generous backing from the government.
In a market of one billion potential patients, 15 biotech products for health are already on the market, with another 60 in the pipeline, Singer said.
Exhibit A: Gendicine, the first gene therapy product approved after clinical trials anywhere in the world.
A recombinant human adenovirus, Gendicine carries the p53 gene and is administered by injection directly into cancerous tumours in the head and neck, including nasopharyngeal carcinoma.
More than 5,000 patients have received the treatment in combination with radiotherapy, including 400 foreign patients from outside China.
The company became profitable shortly after the launch of the product, approved in 2005 by China's State Drug and Food Administration (SDFA).
That, as it turns out, was not an unimpeachable recommendation.
The SDFA's former director, Zheng Xiaoyu, was executed in July 2007 for accepting bribes in return for issuing drug approvals without proper review.
As a result, a staggering 170,000 licenses granted by the SDFA, especially between 1999 and 2002, are currently under review.
Another company, Shenzhen Beike Technologies, provides a treatment based on umbilical cord and bone marrow stem cells for Alzheimer's, autism, brain trauma, cerebral palsy and spinal cord injury, as well as a dozen other diseases and conditions. The medication is injected directly into the spinal cord of patients.
"There is no need to do clinical trials for this kind of procedure in China," said the study's lead author, Sarah Frew, also a researcher at McLaughlin-Rotman.
"The approach this company is taking is trying the thing on patients rather than doing scientific research," added Singer.
The product has nonetheless been a commercial success, first with Chinese patients and more recently with international patients. When Frew visited the clinic a year ago, there were a dozen foreigners present.
The company's website is filled with glowing testimonials on the effectiveness of the treatment, which costs tens of thousands of dollars.
In most cases the therapies and vaccines developed in China are far less controversial. Indeed, more than 90 percent of products produced in the health biotech sector are biogenerics, with novel products accounting for 3-to-5 percent of the total.
A more recent development are international joint ventures and investment. Shenzhen Chipscreen Biosciences, for example, has developed an anti-cancer drug in cooperation with Huya Bioscience, based in San Diego, California. Once the medication is on the market, the Chinese partner will hold the rights for China, while Huya can lay claim to the rest of the world.
WuXi PharmaTech, which was listed on the New York Stock Exchange in the summer of 2007, is the first biotech service company in China with major foreign clients, including US pharmaceutical giant Merck and Britain's AstraZeneca.
The fact that WuXi has attracted such companies "punctures a little bit the legend that there is no intellectual property in China," said Singer.
Another myth that may soon fall by the wayside is that China can only reproduce what other have done already.
"There is no longer a hegemony on the part of industrialised countries in global biotech innovation," Singer said.
Subscribe to:
Posts (Atom)